99 related articles for article (PubMed ID: 8622053)
1. CA-125: an evolving role in the management of ovarian cancer.
Markman M
J Clin Oncol; 1996 May; 14(5):1411-2. PubMed ID: 8622053
[No Abstract] [Full Text] [Related]
2. Ovarian cancer patients with high CA-125 but no symptoms--should antiangiogenic treatments be considered?
Sharma A; Bernacki RJ
Oncol Res; 1997; 9(2):53-4. PubMed ID: 9167185
[TBL] [Abstract][Full Text] [Related]
3. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Markman M
Cancer; 2008 Nov; 113(10):2832-3; author reply 2833-4. PubMed ID: 18846540
[No Abstract] [Full Text] [Related]
4. Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy.
Markman M; Kennedy A; Kim J
Gynecol Oncol; 2001 Dec; 83(3):593-5. PubMed ID: 11733977
[TBL] [Abstract][Full Text] [Related]
5. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Markman M
Gynecol Oncol; 2009 Jul; 114(1):136-7; authore reply 137. PubMed ID: 19138792
[No Abstract] [Full Text] [Related]
6. [The evaluation of the efficacy of adjuvant laferon therapy in the combined treatment of patients with ovarian cancer based on the monitoring of the tumor marker Ca-125 in the blood serum].
Zhyl'chuk VIe; Alistratov OV; Vorontsova AL
Lik Sprava; 1998; (2):137-9. PubMed ID: 9670686
[TBL] [Abstract][Full Text] [Related]
7. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
Tuxen MK; Sölétormos G; Dombernowsky P
Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
[TBL] [Abstract][Full Text] [Related]
8. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.
Bridgewater JA; Nelstrop AE; Rustin GJ; Gore ME; McGuire WP; Hoskins WJ
J Clin Oncol; 1999 Feb; 17(2):501-8. PubMed ID: 10080591
[TBL] [Abstract][Full Text] [Related]
9. Use of CA 125 in follow-up of ovarian cancer.
Rustin G; Tuxen M
Lancet; 1996 Jul; 348(9021):191-2. PubMed ID: 8684165
[No Abstract] [Full Text] [Related]
10. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials.
Rustin GJ; Nelstrop AE; Bentzen SM; Bond SJ; McClean P
J Clin Oncol; 2000 Apr; 18(8):1733-9. PubMed ID: 10764434
[TBL] [Abstract][Full Text] [Related]
11. Tumour markers in ovarian cancer.
Kehoe S; Selman T
Hosp Med; 2001 Aug; 62(8):452-3. PubMed ID: 11530581
[No Abstract] [Full Text] [Related]
12. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.
Rustin GJ; Nelstrop AE; McClean P; Brady MF; McGuire WP; Hoskins WJ; Mitchell H; Lambert HE
J Clin Oncol; 1996 May; 14(5):1545-51. PubMed ID: 8622070
[TBL] [Abstract][Full Text] [Related]
13. Cancer of the ovary.
Cannistra SA
N Engl J Med; 2004 Dec; 351(24):2519-29. PubMed ID: 15590954
[No Abstract] [Full Text] [Related]
14. Early versus delayed treatment of relapsed ovarian cancer.
Rustin G; van der Burg M; Griffin C; Qian W; Swart AM
Lancet; 2011 Jan; 377(9763):380-1. PubMed ID: 21277438
[No Abstract] [Full Text] [Related]
15. Predicting surgical outcome for advanced ovarian cancer, surgical standards of care, and the concept of kaizen.
Bristow RE
Gynecol Oncol; 2009 Jan; 112(1):1-3. PubMed ID: 19100914
[No Abstract] [Full Text] [Related]
16. The prognostic value of CA-125 in epithelial ovarian cancer patients during and after chemotherapy.
Lukácskó I; Hernádi Z; Sápy T; Borsos A
Acta Chir Hung; 1997; 36(1-4):213-4. PubMed ID: 9408350
[TBL] [Abstract][Full Text] [Related]
17. Use of CA-125 to assess response to new agents in ovarian cancer trials.
Rustin GJ
J Clin Oncol; 2003 May; 21(10 Suppl):187s-193s. PubMed ID: 12743133
[TBL] [Abstract][Full Text] [Related]
18. Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Kang S; Kim TJ; Seo SS; Kim BG; Bae DS; Park SY
Gynecol Oncol; 2011 Jan; 120(1):18-22. PubMed ID: 21035174
[TBL] [Abstract][Full Text] [Related]
19. CA-125 blood test in early detection of ovarian cancer.
Burki TK
Lancet Oncol; 2015 Jun; 16(6):e269. PubMed ID: 25975633
[No Abstract] [Full Text] [Related]
20. Serum levels of CA 125 and TPS during treatment of ovarian cancer.
Van Dalen A; Favier J; Baumgartner L; Hasholzner U; De Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
Anticancer Res; 2000; 20(6D):5107-8. PubMed ID: 11326677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
